Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar 15;26(143):160111.
doi: 10.1183/16000617.0111-2016. Print 2017 Jan.

Pulmonary endarterectomy in the management of chronic thromboembolic pulmonary hypertension

David Jenkins  1 , Michael Madani  2 , Elie Fadel  3 , Andrea Maria D'Armini  4 , Eckhard Mayer  5
Affiliations
Review

Pulmonary endarterectomy in the management of chronic thromboembolic pulmonary hypertension

David Jenkins et al. Eur Respir Rev. .

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is a type of pulmonary hypertension, resulting from fibrotic transformation of pulmonary artery clots causing chronic obstruction in macroscopic pulmonary arteries and associated vascular remodelling in the microvasculature.Pulmonary endarterectomy (PEA) offers the best chance of symptomatic and prognostic improvement in eligible patients; in expert centres, it has excellent results. Current in-hospital mortality rates are <5% and survival is >90% at 1 year and >70% at 10 years. However, PEA, is a complex procedure and relies on a multidisciplinary CTEPH team led by an experienced surgeon to decide on an individual's operability, which is determined primarily by lesion location and the haemodynamic parameters. Therefore, treatment of patients with CTEPH depends largely on subjective judgements of eligibility for surgery by the CTEPH team.Other controversies discussed in this article include eligibility for PEA versus balloon pulmonary angioplasty, the new treatment algorithm in the European Society of Cardiology/European Respiratory Society guidelines and the definition of an "expert centre" for the management of this condition.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Disclosures can be found alongside this article at err.ersjournals.com

Figures

FIGURE 1
FIGURE 1
Effects of pulmonary vascular resistance (PVR) at diagnosis on in-hospital and 1-year mortality in patients with chronic thromboembolic pulmonary hypertension (CTEPH) undergoing pulmonary endarterectomy. Data from the international CTEPH registry [23]. *: p<0.05 compared with group with PVR >1200 dyn·s·cm-5.
See this image and copyright information in PMC

References

    1. Galiè N, Humbert M, Vachiery JL, et al. . 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Respir J 2015; 46: 903–975. - PubMed
    1. Kim NH, Delcroix M, Jenkins DP, et al. . Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol 2013; 62: Suppl. 25, D92–D99. - PubMed
    1. Lang IM, Pesavento R, Bonderman D, et al. . Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J 2013; 41: 462–468. - PubMed
    1. Lang IM, Madani M. Update on chronic thromboembolic pulmonary hypertension. Circulation 2014; 130: 508–518. - PubMed
    1. Pepke-Zaba J, Delcroix M, Lang I, et al. . Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 2011; 124: 1973–1981. - PubMed

MeSH terms